JEPeM

JEPEM is a French biotechnology company focused on developing innovative immunotherapies for the treatment of cancer. Based in Marseille, the company specializes in targeting the adenosine pathway within the tumor microenvironment to restore anti-tumor immune responses. Their primary research efforts center on the development of monoclonal antibodies targeting CD39 and CD73, enzymes that play a critical role in immunosuppression. By inhibiting these targets, JEPEM aims to overcome resistance to current checkpoint inhibitors and provide new therapeutic options for patients with solid tumors. The company operates as a spin-off from the Centre de Recherche en Cancérologie de Marseille (CRCM).